Vera Therapeutics

Contributing Author

Recent Articles by Vera Therapeutics

Nov-10	Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit VERA GlobeNewswire
Nov-07	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy VERA GlobeNewswire
Nov-07	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Nov-06	Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine VERA GlobeNewswire
Nov-05	Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results VERA GlobeNewswire
Oct-22	Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET VERA GlobeNewswire
Oct-17	Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 VERA GlobeNewswire
Oct-10	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Sep-05	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Aug-26	Vera Therapeutics to Participate at Upcoming Investor Conferences VERA GlobeNewswire
Aug-08	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Aug-05	Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results VERA GlobeNewswire
Jul-10	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Jun-09	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
Jun-04	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference VERA GlobeNewswire
Jun-03	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans VERA GlobeNewswire
Jun-02	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy VERA GlobeNewswire
May-09	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VERA GlobeNewswire
May-06	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results VERA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.